Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

NCT06193759 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Medulloblastoma, Childhood
Atypical Teratoid/Rhabdoid Tumor of CNS
Embryonal Tumor With Multilayered Rosettes
Pineoblastoma
Embryonal Brain Tumor Not Otherwise Specified
Ependymoma

Interventions

BIOLOGICAL: Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA)
DRUG: Group A Standard-of-Care Backbone Therapy
RADIATION: Group B Salvage Backbone Therapy

Sponsor

Children's National Research Institute